The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It does say "interim analysis" but would there be any point recruiting another 11? Surley they wouldnt need to and could use the data recieved to make a decision on phase 3 trials!
To me that means they have stopped the COPD trial now and are analising the data and the results can be expected sometime within the next 3 months. Whats not clear is if they going to start recruiting the final 11 required at some point, or if thats it, the end of the trial?
Nolupus - It would be good to get a second opinion this statement.
"The Company has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to conduct an unplanned interim analysis on the grounds that data from the 109 COPD patients with confirmed viral infection generates useful safety, biomarker and potentially efficacy data to support ongoing trials of SNG001 in COVID-19 patients. The results of this interim analysis are expected this Summer."
How would they deduce efficacy data if it remained in a blinded format?
It’s natural for everyone to try and read into an RNS - is it good, bad, indifferent. Frankly, for me, the whole market is confused with vaccines, antibodies, treatments. Some are worried SNG will be too late, yet the mention of another vaccine hopeful in the US that’s not even started phase 1 sends the DOW soaring higher- so are we too late, too early, will there be another spike on re-opening the economy? It strikes me nobody can be sure either way. Covid gave SNG a great opportunity to accelerate trial numbers. It was never the original plan for the treatment. Flu and colds and many other viruses can be really dangerous for those with asthma and COPD too. No, I am not a medical expert and I recognise that - but I have been here since Jan and don’t intend to go anywhere. Safe enough for people to take this in their own home, great! Because the trials take time we are going to drift, because this will likely be a yes/no game changes once the results are in and once they are in that will be that. Easily news at some point with direction of travel, who knows.
Rich. With respect, I have watched this board for months. I have seen a lot of genuine posts.
My argument like yours is that we are not lung disease experts. Medicine can go anywhere.
Their appears some genuine posters here Richard. Give them a break chap.
Best wishes.
Ghia - I don't think the numbers recruited in the trial is something particularly to worry about. That is what it is. Delays aren't great but they're immaterial in the grand scheme of things. It's obviously hard to read anything concrete into the RNS but if I had to guess, and it is a guess, I'd find it more likely they're doing a home trial, if the hospital trial wasn't having blockbusting success. If it was I don't think they'd bother. I simply think that it's slightly more likely that it's having a mild/moderate impact in hospital and they think they might see better results if they catch it early. If that's the case, it doesn't mean it's a write-off, and may still do well from home. Of course it could be doing well in hospitals too - but we just don't know obviously.
GHia,
I would suggest you read the part about the COPD trial again :-)
My reading is not the same as yours
Woodstock - I agree or at least its presented in a way that almost implies a backward step. But there are some nuggets of new news in there.
The Home Trial has been officially started for one so you could be enrolled as of today.
COPD trial has been allowed to finish with only 109 recruited and data can be unblinded.
We can dose the most vulnerable people over 50.
But people are really latching onto the July delay and only 98 rcruited, and I get it delays are always disappointing.
The trouble with todays press releases is, it is old news. Hence the market reflection of current sp.